No21Vol1.indd
|
|
- あきお さんきち
- 5 years ago
- Views:
Transcription
1 ( ): - PSA Shojiro Kano Head, Working Group of PSA Testing Standardization Committee (PSA) PSA PSA JCCLS PSA A PSA B PSA PSA Wang PSA FDA Hybritech Tandem-R PSA
2 PSA PSA PSA - (ACT) - (AMG) ACT (PSA-ACT) PSA PSA (Free PSA) PSA-ACT, PSA-ACT PSA PSA-ACT Free PSA PSA (Total PSA) PSA PSA PSA Stanford NCCLS PSA PSA PSA PSA PSA-ACT PSA-ACT PSA-ACT Free PSA : : standard WHO IFCC (primary standard) NIBSC PSA PSA Tandem-R PSA PSA Free PSA (skewed response) PSA Free PSA PSA-ACT (equimolar response) PSA PSA ( )
3 Stanford Free PSA PSA- ACT Free PSA PSA-ACT Free PSA PSA-ACT PSA ad hoc ( ) Free PSA PSA-ACT - ) PSA ( ) PSA : standard ( ) (JCCLS) PSA ( ) PSA - ) PSA PSA PSA PSA AMG AMG Zn Hybritech ( ) Free PSA AMG ph. M NaOH ph. M HCl
4 ph.. mm - ) ( ) PSA Free PSA PSA-ACT consensus method PSA - ) ( ) C ( ) ( ) Stanford Free PSA PSA-ACT.. ng/ml ( ) (Free PSA PSA-ACT ) ( ). ( ) ( ) PSA (Free PSA PSA- ACT) ( ) ( ) ( )
5 PSA PSA-ACT Free PSA PSA-ACT Free PSA PSA-ACT - ) ELISA ( : standard) PSA AMG PSA PSA WHO PSA WHO PSA
6 PSA PSA PSA PSA Free PSA PSA-ACT PSA SR ( ) ( ) ( ) ( ) ( SR ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Lilja H, Christensson A, Dahlen U, et al: Prostate-specifi c antigen in serum occurs predominantly in complex with a -antichymotrypsin Clin Chem., : -,. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate specifi c antigen and a -antichymotrypsin is the major form of prostate specifi c antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer Cancer Res., : -,. NCCLS Primary Reference Preparations Used to Standardize Calibration of Immunochemical Assays for Serum Prostate Specifi c Antigen (PSA); Approved Guideline NCCLS document I/LA -A NCCLS, Pennsylvania, USA,. PSA, : -,. PSA PSA ad hoc, : -,. PSA PSA
7 , ( ): -,. S Kano, M Ishibashi, K Kuwa, Y Itoh, W Tani, K Shimazu, K Abe, K Fujihashi and T Yoshikai: Successful Preparation of Serum-Based Secondary Reference Material for Standardization of Total Prostate-Specific Antigen (PSA) Immunoassays Proceeding of th European Congress of Clinical Chemistry and Laboratory Medicine, -,. PSA, (S ), -,. A PSA ) ) ) ( SR ( SR ) B:PSA WG JCCLS WG Dr. Harry G. Rittenhouse (Beckman Coulter, Inc) ICCC Kyoto Luncheon seminar
8 PSA standardization; biochemical & analytical implication WG ICCC Kyoto Dr. Robert M. Nakamura (Scripps Clinic) JCCLS WG JCCLS WG Dr. Sephen D. Mikolajczyk (Hybritech; Beckman Coulter Inc) prostatespecific antigen (total PSA) ( ) PSA Dr. Peter Bialk (Roche Diagnostics GmbH) WG EuroMedLab Barcelona Successful preparation of serumbased secondary reference material for standardization of total prostate-specifi c antigen (PSA) immunoassays WG WG WG WG Survey
9 WG WG Survey WG WG JCCLS WG WG WG C. PSA. Survey. Survey. Survey..... Base Buffer Base Serum... Free PSA PSA-ACT. Free PSA (A) (B, B')... Free PSA (A).. (,,,, ) (C ). (C) (C ) (C C ). Outlyer (C ) (C C ). Precision Profile. Precision Profile Outlyer
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
: / FDA HBsAg HIV 1/2 HCV : QMS : 3.5% IgM () 1.0% H317 - H334 - : : :: : QMS Everolimus : 6.4% (II) H400 - H % SDS QMS EDTA (K 3 ) EDTA (K 2 )
QMS (EVER) 0373852 (QMS) QMS QMS X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
More informationTaro12-認定-部門-ASG101-06
JIS Q 17025(ISO/IEC 17025(IDT)) JIS Q17025(ISO/IEC 17025(IDT)) --- --- JNLA JCSS ISO/IEC 17025 JIS Q 17025 IAJapan ILAC APLAC JIS Q17011 ISO/IEC 17011 MRA ILACAPLAC MRA IAJapan (3) JNLAJCSS (4) testing
More information18 20 A1c C HDL-LDL-C- A1c C CRP CRP ID-MS RF(PRL)(LH) (FSH)E2TSH -(hcg) AFPCEA)(FCM) RFPRLE2TSHhCGAFP CEA
18 19 5 18 20 A1c C HDL-LDL-C- A1c C CRP CRP ID-MS RF(PRL)(LH) (FSH)E2TSH -(hcg) AFPCEA)(FCM) RFPRLE2TSHhCGAFP CEA Title : Research and Development to Promote the Creation and Utilization of an Intellectual
More informationJIS Z 9001:1998JIS Z 9002:1998 ISO/IEC 17025ISO/IEC Guide 25
JIS Q 17025 IDT, ISO/IEC 17025 IT JIS Z 9001:1998JIS Z 9002:1998 ISO/IEC 17025ISO/IEC Guide 25 JIS Q 17025 IDT, ISO/IEC 17025 IT IT JIS Q 17025ISO/IEC 17025 (2) JIS Z 9358 ISO/IEC Guide 58 (3) testing
More information-. -. CD Threshold Noise Discrimination CD CDbight+ CDdim CD は
CD34 JCCLS H3-P V1.0 Report of the Hematology Standardization Committee Guidelines for CD34+ Cell Determination by Flow CytometryJCCLS H3-P V1.0 日本臨床検査標準協議会血液検査標準化検討委員会フローサイトメトリーワーキンググループ Japanese Committee
More information2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
More informationuntitled
WG 2013 P P P P WG WG P WG 12 12 P P20 200 200 200 200 2011 2012 2012 11 1 2 21 2 2 1 2 2 2 2 1 2 1 2 11 720,450(8.0) 37,845(0.4) 4) 37.7 7 5.4 0.1 8,299,154(91.6)
More informationuntitled
19 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - -
More informationSI SI CIPM MRA
JAB RL331-2008 2008 11 1 2008 9 1 2008-09-01-1/25-1 2008-11-01 ... 3... 3... 4 3.1...4 3.2...4... 5... 7... 8 6.1...8 6.1.1 SI...8 6.1.2 SI...9 6.2...9 6.3...9 6.4...10... 10 7.1 CIPM MRA...10 7.2 135...11
More informationFig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal
More information表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
More informationJAMSTEC Rep. Res. Dev., Volume 12, March 2011, 27 _ 35 1,2* Pb 210 Pb 214 Pb MCA 210 Pb MCA MCA 210 Pb 214 Pb * 2
JAMSTEC Rep. Res. Dev., Volume 12, March 2011, 27 _ 35 1,2* 1 1 1 1 210 Pb 210 Pb 214 Pb MCA 210 Pb MCA MCA 210 Pb 214 Pb 2010 10 4 2010 12 10 1 2 * 237-0061 2-15 046-867-9794 ogurik@jamstec.go.jp 27 210
More informationHPV HPV HPV HPV 7 HPV 8 9 HPV 3 HPV HPV HPV , Becker Ajzen H
3 26 3 Journal of Junshin Gakuen University, HPV Faculty of Health Sciences Vol.3, March 2014 99 HPV Knowledge of and attitudes towards human papillomavirus vaccinations among mothers who have daughters
More informationO-1 O-2 O-3 O-4 O-5 O-6
18 The 18 th Congress of Hokkaido Association for Clinical Engineering Technologists 930940 O-1 O-2 O-3 O-4 O-5 O-6 O-7 O-8 O-9 O-10 O-11 O-12 O-13 O-14 O-15 O-16 O-17 O-18 O-19 O-20 O-21 O-22 O-23 O-24
More informationThe Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
More information国際的血球基準器としてのコールターカウンターモデルZBIの機能
Validity of the Coulter Counter model ZBI as an international standard blood cell analyzer Yasunori Kondo, Rie Yoshida and Motonori Nakamura The standard analytical method (reference method) for blood
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationMRA CIPM-MRA Mutual Recognition Arrangement OIML-MAA Mutual Acceptance Arrangement ILAC-MRA 3 CIPM-MRA (Associate to CGPM)+2 (As o
VIM JIS JLAC 20 2008.9.24 1 VIM JIS VIM GUM JCGM JIS 3 GUM JIS 2 MRA CIPM-MRA Mutual Recognition Arrangement OIML-MAA Mutual Acceptance Arrangement ILAC-MRA 3 CIPM-MRA 1999 38+2 71+2 45+26(Associate to
More information平成26年度 化学物質分析法開発報告書
2,2-2,2 -Iminodiethanol Diethanol amine CAS 111-42-2 C 4 H 11 NO 2 105.1356-105.0790-28 C 1) 1.0881 g/cm 3 1)
More informationDETECTION OF PROSTATE CANCER IN UROLOGICAL PRACTICE: Clinical Establishment of Serum PSA Reference Values by Age Haruki Yamazaki, Yasuyuki Suzuki, Ats
DETECTION OF PROSTATE CANCER IN UROLOGICAL PRACTICE: Clinical Establishment of Serum PSA Reference Values by Age Haruki Yamazaki, Yasuyuki Suzuki, Atsushi Madarame, Nobuki Katoh and Fujio Masuda Department
More informationuntitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
More informationこの添付文書をよく読んでから使用してください 体外診断用医薬品 ** 2018 年 3 月改訂 ( 第 6 版 ) * 2017 年 9 月改訂 ( 第 5 版 ) 製造販売承認番号 21200AMY 遊離型前立腺特異抗原キット フリー PSA アボット ja Free PSA 7K
この添付文書をよく読んでから使用してください 体外診断用医薬品 2018 年 3 月改訂 ( 第 6 版 ) 2017 年 9 月改訂 ( 第 5 版 ) 製造販売承認番号 21200AMY00127000 遊離型前立腺特異抗原キット フリー PSA アボット ja Free PSA 7K71 G04345R05 B7K71J 重要な基本的注意 フリー PSA 値はトータル PSA 値との比 ( フリー
More informationFIBA In Memoriam
ICH 日本シンポジウム 2016 ( 第 35 回 ICH 即時報告会 ) 平成 28 年 12 月 14 日全電通ホール M10 生体試料中薬物濃度分析法バリデーション Bioanalytical Method Validation 石井明子 M10 ラポーター国立医薬品食品衛生研究所生物薬品部 International Council for Harmonisation of Technical
More informationがん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性
2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
More informationX線分析の進歩36 別刷
X X X-Ray Fluorescence Analysis on Environmental Standard Reference Materials with a Dry Battery X-Ray Generator Hideshi ISHII, Hiroya MIYAUCHI, Tadashi HIOKI and Jun KAWAI Copyright The Discussion Group
More information平成26年度 化学物質分析法開発報告書
2,2-2,2 -Iminodiethanol Diethanol amine CAS 111-42-2 C 4 H 11 NO 2 105.1356-105.0790-28 C 1) 1.0881 g/cm 3 1)
More information野岩鉄道の旅
29th 5:13 5:34 5:56 6:00 6:12 6:20 6:21 6:25 6:29 6:31 6:34 6:38 6:40 6:45 6:52 6:56 7:01 7:07 7:11 7:32 7:34 7:50 7:58 8:03 8:17 8:36 8:44 5:50 5:54 6:15 6:38 6:39 6:51 6:59 6:59 7:03 7:08 7:08 7:11 7:15
More information免疫Ⅱ
100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC
More information3 1 2
Agilent 4200 TapeStation Agilent 4200 TapeStation 3 1 2 2 3 ScreenTape 3 Agilent 4200 TapeStation QC Agilent 4200 TapeStation Ready-to-use ScreenTape 8 PCR 96-well plate 1 96 1 qrt-pcr DNA RNA DNA / RNA
More information04菊池氏.indd
KIKUCHI Sakae 1 1 1899 32 2000 1966 1.58 1990 1.57 2000.15 2 32 13 2 3 4 18 39.6 25 216,974 106,594 110,380 12 22 5 4.72 12 6 25 33 60 90 25 35 23 24 3 25 7 25 35 45 2 2002.9 4 1925 2003 1997 8 1975 25
More information1 911 34/ 22 1012 2/ 20 69 3/ 22 69 1/ 22 69 3/ 22 69 1/ 22 68 3/ 22 68 1/ 3 8 D 0.0900.129mm 0.1300.179mm 0.1800.199mm 0.1000.139mm 0.1400.409mm 0.4101.199mm 0.0900.139mm 0.1400.269mm 0.2700.289mm
More information1 2 http://www.japan-shop.jp/ 3 4 http://www.japan-shop.jp/ 5 6 http://www.japan-shop.jp/ 7 2,930mm 2,700 mm 2,950mm 2,930mm 2,950mm 2,700mm 2,930mm 2,950mm 2,700mm 8 http://www.japan-shop.jp/ 9 10 http://www.japan-shop.jp/
More information第18回海岸シンポジウム報告書
2011.6.25 2011.6.26 L1 2011.6.27 L2 2011.7.6 2011.12.7 2011.10-12 2011.9-10 2012.3.9 23 2012.4, 2013.8.30 2012.6.13 2013.9 2011.7-2011.12-2012.4 2011.12.27 2013.9 1m30 1 2 3 4 5 6 m 5.0m 2.0m -5.0m 1.0m
More information液晶ディスプレイ取説TD-E432/TD-E502/TD-E552/TD-E652/TD-E432D/TD-E502D
1 2 3 4 5 6 7 1 2 3 4 5 6 7 2 2 2 1 1 2 9 10 11 12 13 14 15 16 17 1 8 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10 9 11 12 13 13 14 15 16 17 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 11 12
More information000-.\..
1 1 1 2 3 4 5 6 7 8 9 e e 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 10mm 150mm 60mm 25mm 40mm 30mm 25 26 27 1 28 29 30 31 32 e e e e e e 33 e 34 35 35 e e e e 36 37 38 38 e e 39 e 1 40 e 41 e 42 43
More information1 1 36 223 42 14 92 4 3 2 1 4 3 4 3429 13536 5 6 7 8 9 2.4m/ (M) (M) (M) (M) (M) 6.67.3 6.57.2 6.97.6 7.27.8 8.4 5 6 5 6 5 5 74 1,239 0 30 21 ( ) 1,639 3,898 0 1,084 887 2 5 0 2 2 4 22 1 3 1 ( :) 426 1500
More information1 C 2 C 3 C 4 C 1 C 2 C 3 C
1 e N >. C 40 41 2 >. C 3 >.. C 26 >.. C .mm 4 C 106 e A 107 1 C 2 C 3 C 4 C 1 C 2 C 3 C 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124
More information(1519) () 1 ( ) () 1 ( ) - 1 - - 2 - (1531) (25) 5 25,000 (25) 5 30,000 25,000 174 3 323 174 3 323 (1532) () 2 () 2-3 - - 4 - (1533) () 1 (2267)204 () (1)(2) () 1 (2267)204 () (1)(2) (3) (3) 840,000 680,000
More information平成24年財政投融資計画PDF出後8/016‐030
24 23 28,707,866 2,317,737 26,390,129 29,289,794 2,899,665 24 23 19,084,525 21,036,598 1952,073 24 23 8,603,613 8,393,427 967,631 925,404 202,440 179,834 217,469 219,963 66,716 64,877 3,160,423 2,951,165
More information[mm] [mm] [mm] 70 60 50 40 30 20 10 1H 0 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6 7 8 9 10 11 12 60 50 40 30 20 10 0 18 19 20 21 22 23 24 1 2 3 4
More informationGreen Light GxP HPLC 2
Excellence Plus Good Manufacturing Practice (GMP) 1 (OOS) (OOT) (OOE) 2 2 3 5 5 5 8 8 LevelControl 8 9 profact profact Advanced 9 TestManager 11 11 12 Green Light GxP HPLC 2 GMP GLP (USP) FDA (PAI) 7346.832
More information437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
More information5 CSF 6 CSF 7 CSF CSF CDV CDV GFAP CSF Pandy test NSE MBP LDH mu/ml 0-5 /µl AST mu/ml CK mu/ml <25 mg/dl<45 mg/dl GLU
CT MRI CSFCSF CSF CSF CSF CSF CSF (cisternal puncture) CSF 20-23G 90 (20-23G) : CSF
More informationNL16-1_0329
No.16-1 March. 2012 JAMTTC News Letter http://jamttc.umin.jp/ Japanese Association for Molecular Target Therapy of Cancer 135-85503-8-31 TEL: 03-3520-0111 ext.5413 FAX: 03-3570-0484 ...1 JAMTTC2012...2...3...4...5
More informationKey words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81
More informationJAB RL504:201 JAB NOTE 4 2 January 25, A B
JAB RL504:201 JAB NOTE 4 JAB RL504:201 2201125 1200025 200-0-25-1/- 2 201-01-25 JAB RL504:201 JAB NOTE 4 2 January 25, 201............... 6 5.1... 6 5.2... 6 5. A... 7 5.4 B... 7 5.5... 8 5.6... 9 5.7...
More informationGB 3rd edition final.ppt
Complementary and Alternative Medicine (National Center for Complementary and Alternative Medicine; NCCAM) Complementary and alternative medicine is a group of diverse medical and health care systems,
More informationflF™m…−…n„Efic’æ’¶
44 2006 Cognitive Rehabilitation by means of Personal Computer for Cerebrovascular Disease Patients with Attentional Disorders 1 1 2 2 5 4 1 PC ABA design 4 PASATTMT Ponsford PC SAS working memoryattention
More informationCA CA19-9 CA19-9 CA CA CA19-9 ARCHITECT i 2000SR CLIA U/mL CA % CA CA
原 著 30 22-29, 2015 CA19-9 CA19-9 CA19-9 2006 12013 6 CA19-9 32,508 37.0U/mL 790 2 CA19-9 320 CA19-9 ARCHITECT i 2000SRCLIA 0.0 37.0U/mL 8 4 1 2 18CA19-9 198.2 46.4 2,968 U/mL 5 3 2.5% CA19-9 2.5% CA19-9
More informationDocHdl1OnPRS1tmpTarget
2015; 26 6 : 658-668 自己免疫性出血病 FXIII/13 診断ガイド Guidance on Diagnostic Criteria for Autoimmune Hemorrhaphilia FXIII/13(AHFXIII/13) FXIII/13 659 Contents 1 660 2 660 3 660 4 661 5 661 6 661 7 661 8 661 9 662
More information. 1 EBM Evidence-Based Medicine JCAHO 2
1 1 . 1 EBM Evidence-Based Medicine JCAHO 2 . 2 3 . 4 . 5 . When Where Who What Why How 6 . 7 3 DPC . 20 30 8 20 30 . (1) 9 3 BP mm mm . (2) 10 . http://epath.medis.or.jp/ 11 . 12 . 13 . 14 15 . PDCA Plan
More informationCH 2 CH CH 2 CH CH 2 CH CH 2 CH 2 COONa CH 2 N CH 2 COONa O Co 2+ O CO CH 2 CH N 2 CH 2 CO 9 Change in Ionic Form of IDA resin with h ph CH 2 NH + COO
CH 2 CH CH 2 CH CH 2 CH CH 2 CH 2 COONa CH 2 N CH 2 COONa O Co 2+ O CO CH 2 CH N 2 CH 2 CO 9 Change in Ionic Form of IDA resin with h ph CH 2 NH + COOH COOH COOH COO - CH 2 NH + + CH 2 NH COO - COO - COO
More informationuntitled
twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical
More informationuntitled
JIS A 12190000 Method for standard penetration test 2005 1 ISO 22476-3:2005 J J 1 SPTSPT 63.5 kg 760 mm SPT N SPT 300 mm N A 2 ISO 22475-1,Geotechnical investigation and testing Sampling methods and groundwater
More informationSteel Construction Engineering Vol.3 No.12(December 1996)
Applicability of Notinal Load - Plastic Hinge Analysis to Structural Design of Steel Frames ABSTRACT ; Plastic hinge method inherently assumes the elastic-perfectly plastic momentcurvature relation which
More information臨床神経45-1.indb
59 Case of the Issue No. 9 carpal tunnel syndrome: CTS CTS CTS CTS nerve conduction study; NCS needle electromyography; nemg NCS carpal tunnel syndrome: CTS 1 CTS 4 CTS 45 65 1 3 2 CTS CTS 1999 American
More information356 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /., No.1, -/0-0+ (,**1) 44 For Quality Control and Quality Assurance in Food Analysis Akemi Yasui Analyt
356 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /., No.1, -/0-0 (,**1) 44 For Quality Control and Quality Assurance in Food Analysis Akemi Yasui Analytical Science Division, National Food Research Institute,
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More informationJapanese.PDF
2002 11 2 3 Part I 4 5 6 3.1WTO/TBT 2 3 6 3.2ISO/IEC 7 3.3 7 3.4 7 3.5 8 3.6 8 9 4.1 9 4.2 9 4.3 10 12 Part II 13 1.1 13 1.2 13 1.3 14 1.4 14 1.5 14 2 14 3 15 3.1 15 3.2 16 3.3 17 3.4 17 3.5 18 3.6 18
More informationTissueGnostics HistoFAXS TissueGnostics HistoFAXS HistoFAXS 最新の技術に裏づけられた細胞解析システム HistoFAXS HistoFAXS HistoFAXS HistoFAXS Zeiss 2 HistoFAXS HistoQuest
HistoFAXS 最新の技術に裏づけられた細胞解析システム HistoFAXS HistoFAXS HistoFAXS HistoFAXS Zeiss 2 HistoFAXS HistoFAXS 200ROI FOV Forward Connection Backward Connection/Gating mm 2 mean value HistoFAXS ワークフロー 100x HistoFAXS
More informationTable 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
More information000..\..
Bull. Nagoya Univ. Museum No. 20, 79 91, 2004 Quantitative chemical analysis of rocks with X-ray fluorescence analyzer XRF-1800 NAKAZAKI Mineko TSUBOI Motohiro KANAGAWA Kazuyo KATO Takenori SUZUKI Kazuhiro
More information(印刷)分身主義の森を抜けて‥‥
2 !? 3 Bunshinism Bunshinism Bunshinism 4 P178 P180 5 *1 *1 *2 *2 ( ) P122!? P37 6 > > > ( ) 7 -------------------- -------------------- 8 P54 9 P180 10 > > > etc. 11 P30 P128!? P216 12 () 13 *3 *3 14
More information審査報告書(案)
19 83 7 18 628 1 19 8 3 7 18 6 28 30 MI 31 360 21700BZY00247000 5mm CEA 59 mm 2 50% 80 1. 2. 3 19 8 3 [ ] 7 [ ] [ ] [ ] [ ] 18 6 28 [ ] CEA 49mm 50 80 2 4 carotid endarterectomy CEA 1,2 CEA ECST 3 NASCET
More informationVOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
More informationUnknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ
More informationLetter566.pdf
http://nibs.lin.gr.jp/ 2 2 29 1000 1990 27.4 30.0 2009 13.5 49.6 1995 475 87 2009 292 332 1995 54 22 2009 70 101 57 1 2011 3 3 13 2008 3 2009 5 11 6 4.5 2 cm 3 1 1 2 3 S 100 4 Vimentin Melan A 5 3 HE Canine
More information